Rhabdomyosarcoma: The Experience of Single Institution (original) (raw)
Related papers
Journal of the Egyptian National Cancer Institute, 2006
Our present study is a retrospective analysis of the treatment results of new rhabdomyosarcoma pediatric patients who had attended the pediatric unit clinic of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) from January 1992 to January 2001). Fifty-five new cases of pediatric rhabdomyosarcoma attended the pediatric unit outpatient clinic of (NEMROCK) from the period of January 1992 until January 2001. Patients were divided into 4 stages and classified into low-risk patients and high-risk patients according to the extent of resection. Stage I, II orbital and stage I para-testicular embryonal rhabdomyosarcomas received 32 weeks of vincristine and actinomycin- D (vincristine 1.5 mg/m2 weekly, actinomycin-D 0.015 mg/Kg/day day 1 to day 5). Other pathologies, sites and stages received 52 weeks of chemotherapy. Chemotherapy regimens included VAC (vincristine 1.5 mg/m2 weekly, actinomycin-D 0.015 mg/Kg/day day 1 to day 5 and endoxan 2.2 gm/m2 I.V with mesna every ...
Clinicopathological Profile of Rhabdomyosarcoma in Children
Journal of Bangladesh College of Physicians and Surgeons, 2012
Objectives: To describe the clinical profile as well as histopathological sub-types of Rhabdomyosarcoma in children.Methods: A hospital base prospective observational study was conducted among 20 diagnosed cases of Rhabdomyosarcoma in children, those attending in Hemato-Oncology department of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka in the period between January to December 2009.Results: The peak incidence of Rhabdomyosarcoma was in 1-5 years of age group (n=9, 45%) with mean age 6.83 years with male to female ratio 5.66:1. The common sites of primary tumor was in head and neck region (40%, n=08), followed by genito-urinary tract, 30% (n=06), extremities 20% (n=04), trunk 10% (n=02). The most common clinical presentation was mass lesion 100% (n=20), followed by local pain 25% (n=05), urinary obstructions 15% (n=03) dysphagia, chronic otorrhea, dysuria, haematuria, and proptoses were 10% each (n=02, each); The histological sub-types were Embryonal 6...
The objectives of this study were to describe the clinicopathologic features and treatment outcomes of childhood rhabdomyosarcoma in a resource-constrained setting. All cases of childhood rhabdomyosarcoma seen over a 10-year period (July 2006 to June 2016) at the University College Hospital, Ibadan, Nigeria were reviewed. Data were extracted from the database of the pediatric Hematology/Oncology Unit of the hospital and analyzed. Ethical approval was obtained from the Institutional Ethics Committee. Fifty children were seen comprising 30 men and 20 women with bimodal ages of 4 and 5 years. Median duration of illness was 16 weeks and the most common primary tumor site was the head-and-neck region in 27 (54%) of cases. The histologic subtypes were embryonal in 30 (60%), alveolar in 9 (18%), and not specified in 11 (22%). The Intergroup Rhabdomyosarcoma Study group TNM Pretreatment stages were stage I in 15 (30%), stage III in 17 (34%), and stage IV in 18 (36%). Treatment included chemotherapy, surgery, and radiotherapy and abandoned in 20 (40%) cases. Median survival was 45 weeks (95% confidence interval: 16.4-73.6) and 5 (10%) patients were alive and disease free, 4 years or more after diagnosis. Outcome of childhood rhabdomyosarcoma is poor and early diagnosis and improved access to treatment are recommended.
Rhabdomyosarcoma in adolescents: A CCHE experience
Journal of Solid Tumors, 2015
Objective and aim: A lower outcome of rhabdomyosarcoma in elder children and young adolescents is increasingly recognized. Our aim was to focus on the outcome of elder children and adolescents with rhabdomyosarcoma treated at our Center (CCHE). Patients and methods: Patients between the age 10 and 18 years diagnosed as rhabdomyosarcoma and treated according to IRS-IV, or IRS V protocols determined according to site, stage, and age at diagnosis. Results: Thirty-two children were recruited at Children's Cancer Hospital-Egypt. They were 12 females (37.5%) and 20 males (62.5%), with a mean age of 12.8y. The mean follow up period was 29.4 months (July 2007 till December 2012). Seventeen patient, were allocated to IRS-IV, and 15 patient to IRS-V. The overall survival and failure free survival were 59.1% and 40.4% respectively. Forty six percent of patients had alveolar pathology, 68.8% presented with tumors at unfavorable sites; 37.5% had metastases at presentation; and 21.9% had intracranial extension at presentation. Risk status, clinical grouping and tumor size affected FFS significantly. Local control was done by radiation therapy in 62.5%, surgery alone in 9.4%, and both radiation and surgery in 25%. Conclusion: The outcome of adolescent group showed inferior results compared to younger children. More cooperation and knowledge about RMS, in this age category, can help develop more intensive unified management approach for them.
Rhabdomyosarcoma in Children: A SEER Population Based Study
Journal of Surgical Research, 2011
Objective. To examine incidence and outcomes for pediatric rhabdomyosarcoma (RMS). Methods. The SEER registry was examined for patients with RMS < 20 y old. Results. Overall, 1544 patients were identified for an incidence of 0.4414/100,000 per year. Males outnumbered females 3:2. Tumors were classified as embryonal (67%), alveolar (32%), and pleomorphic (1%). Alveolar and pleomorphic RMS were more common in adolescents, whereas embryonal type was more common in younger children (P [ 0.0001). Pleomorphic (47%) and alveolar (39%) RMS commonly presented with distant disease, in contrast to embryonal (25%). Most patients had surgical resection (81%) and radiotherapy (63%). Overall, 5-and 10-y survival was 60% and 57%, respectively. Univariate analysis identified higher survival for age < 10 y, local stage, favorable site, embryonal type, <5 cm tumor size, and surgical resection. Multivariate analysis identified non-embryonal type (HR 1.451), non-favorable site (HR 1.570), no surgery (HR 1.726), age ‡ 10 y (HR 1.734), 1973-1978 diagnosis year (HR 1.730), and distant disease (HR 3.456) as independent predictors of mortality. Conclusions. Embryonal histology, the most common type of pediatric RMS, presents in young children and has better prognosis than alveolar or pleomorphic types. Patients with embryonal tumors, favorable tumor location, age < 10 y, localized disease, and surgical resection have improved survival.
Survival rate of children with rhabdomyosarcoma and prognostic factors
2007
Survival rate of children with rhabdomyosarcoma and prognostic factors Background: Rhabdomyosarcoma is the most frequent tumor of soft tissue in children. The survival rate of the patients is significantly increased since the 1970s. This study was undertaken to evaluate the 5-and 10-year survival rates of patients with rhabdomyosarcoma in a single center in Iran. Methods: A total of 77 children with rhabdomyosarcoma up to 15 years old who had been treated at the Hematology and Oncology Department in Ali Asghar Children Hospital from 1993 to 2003 were evaluated for their age and gender, as well as histology, stage and primary site of the tumor at diagnosis. Results: The mean age of the patients was 6.58 years (SD=4.02, median 6 years). In this series, 46 patients (59.7%) were male and 31 (40.3%) female, and the mean survival time of patients was 8 years (95% CI: 8-9). The 5-year survival rate was the highest in patients with localized tumor, stage I and II (82.25% and 86.88% respectively). The survival rate of patients with embryonal tumor was 86.8%, in those with primary orbital tumor was 94%, and in those with genitourinary tumor was 85.71%. The 5-and 10-year overall survival rates were 79.54% and 77.92%, respectively. Conclusions: Children with rhabdomyosarcoma of lower stage, embryonal histology, and orbital and genitourinary primary sites had a better survival rate. Poor prognosis was associated with metastasis of the tumor at the time of presentation, alveolar histology (48%), and tumor of the extremities (58%). In our study, only the stage of the tumor was significantly different in the variables (P=0.0077) because of the small number of patients. Children who survived the first 5 years after diagnosis were found to have an excellent survival rate.
Non Metastatic Rhabdomyosarcoma in Children and Adolescents: Prognostic Factors and Survival
Journal of Orthopaedic Science and Research, 2021
Background: Rhabdomyosarcoma (RMS) is the most common softttissue tumor in childhood. We aimed to study the prognostic factors of non-metastatic RMS in Tunisian paediatric patients. Methods: We reviewed data of paediatric patients (aged < 18 years), with histologically confirmed RMS treated in Salah Azaiez Institute for a non-metastatic RMS during 20 years. Prognostic factors were studied and survival data analysed. Results: 75 patients were included (42 males and 33 females). Embryonal RMS was the most common histologic type (72%) followed by alveolar (21%) and pleomorphic (1%). The most frequently affected sites were head and neck (43%) and genito-urinary (28%). 5-year OS and DFS were 50% and 26%, respectively. By univariate analysis, DFS was significantly correlated to chemotherapy, Radiotherapy (RT) and post-surgical RT with p=0.02, 0.003 and 0.01, respectively. No factor was significant in multivariate analysis. By univariate analysis, 5-year 2
Outcome of Rhabdomyosarcoma in First Year of Life: Children's Cancer Hospital 57357 Egypt
Sarcoma, 2013
Background. Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children. Fifty percent of RMS cases occur in the first 10 years of life and less commonly in infants younger than one-year old. These infants require adapted multimodality treatment approaches. Patients and Methods. We analyzed patients' characteristics, treatment modalities, and the outcome for RMS infants treated at Children's Cancer Hospital Egypt (CCHE) between July 2007 and December 2010 and compared them to patients above one year treated on the same protocol. Results. Out of the 126 RMS treated during this period, 18 were below the age of one year. The male: female ratio was 1.25 : 1. The median age at diagnosis was 0.7 ± 0.2 years. Most of the cases (27.8%) were presented in head and neck regions. The estimated 4-years failure-free survival and overall survival for infants were 49 ± 12% and 70 ± 12%, respectively. These failure-free survival rate and overall survival rate did not differ fro...